D-0151-2018 Class II Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-0151-2018 was initiated by Pfizer Inc. on October 20, 2017 and is designated Class II. Reason for recall: SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent The recall status is terminated (terminated June 2, 2020). Affected quantity: 1972 bottles.

Recall Details

Product Type
Drugs
Report Date
January 10, 2018
Initiation Date
October 20, 2017
Termination Date
June 2, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1972 bottles

Product Description

Zoloft (sertraline HCl) tablets 25 mg* 30-count bottle, Rx only, Distributed by Roerig Division of Pfizer Inc., NY, NY, 10017 NDC 0049-4960-30

Reason for Recall

SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent

Distribution Pattern

Nationwide in the USA

Code Information

Lot: S84026